PYXS vs. CRVS, PVLA, TSVT, TNXP, ALLO, INZY, ALDX, CADL, ACB, and SGMT
Should you be buying Pyxis Oncology stock or one of its competitors? The main competitors of Pyxis Oncology include Corvus Pharmaceuticals (CRVS), Palvella Therapeutics (PVLA), 2seventy bio (TSVT), Tonix Pharmaceuticals (TNXP), Allogene Therapeutics (ALLO), Inozyme Pharma (INZY), Aldeyra Therapeutics (ALDX), Candel Therapeutics (CADL), Aurora Cannabis (ACB), and Sagimet Biosciences (SGMT). These companies are all part of the "pharmaceutical products" industry.
Pyxis Oncology vs. Its Competitors
Corvus Pharmaceuticals (NASDAQ:CRVS) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.
Corvus Pharmaceuticals has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.
Corvus Pharmaceuticals currently has a consensus price target of $15.00, indicating a potential upside of 278.79%. Pyxis Oncology has a consensus price target of $9.00, indicating a potential upside of 696.46%. Given Pyxis Oncology's higher probable upside, analysts plainly believe Pyxis Oncology is more favorable than Corvus Pharmaceuticals.
46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 31.3% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 10.6% of Pyxis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Pyxis Oncology had 4 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 4 mentions for Pyxis Oncology and 0 mentions for Corvus Pharmaceuticals. Pyxis Oncology's average media sentiment score of 0.19 beat Corvus Pharmaceuticals' score of -0.10 indicating that Pyxis Oncology is being referred to more favorably in the news media.
Corvus Pharmaceuticals' return on equity of -24.04% beat Pyxis Oncology's return on equity.
Corvus Pharmaceuticals has higher earnings, but lower revenue than Pyxis Oncology. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.
Summary
Corvus Pharmaceuticals beats Pyxis Oncology on 7 of the 13 factors compared between the two stocks.
Get Pyxis Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PYXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pyxis Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:PYXS) was last updated on 7/8/2025 by MarketBeat.com Staff
Free PYXS Stock Alerts